Markets

Castle Biosciences To Present New Data From Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test At ACG 2026 Annual Scientific Meeting And Postgraduate Course

Oct 12, 2026 · 04:34 PM ET· updated 1h ago

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences,

Why It Matters

Castle Biosciences will show new test results at a medical meeting. The results suggest their Barrett's Esophagus test helps doctors make better treatment choices.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CSTL32.84

-1.58 (-4.59%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.